Literature DB >> 14576666

PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma.

Hensin Tsao1, Martin C Mihm, Christine Sheehan.   

Abstract

BACKGROUND: Although various studies have shown mutations of the tumor suppressor gene, PTEN/MMAC1, in primary, metastatic, and cultured cutaneous melanoma specimens, little is known about the pattern of PTEN protein expression in early melanocytic tumor progression.
OBJECTIVE: To further investigate the role of PTEN in melanocytic tumor development.
METHODS: We assessed the level and distribution of PTEN in normal skin, 39 acquired melanocytic nevi, and 30 primary cutaneous melanomas, including lentigo malignas, by immunostaining.
RESULTS: We found high levels of PTEN expression in cutaneous muscles, nerves, and muscular arteries, and moderate-to-high amounts of PTEN in the epidermis, follicular epithelium, and sebaceous and eccrine glands. PTEN staining in cutaneous lymphatics, dermal and periadnexal adventitial fibroblasts, and chondrocytes were variably absent. Junctional melanocytes and chondrocytes frequently exhibited preferential nuclear staining. We found uniformly strong PTEN expression in the cytoplasm of almost all benign and dysplastic nevi. However, there was some evidence of nuclear PTEN loss even in the benign melanocytic proliferations. In addition, out of 30 primary cutaneous melanomas and lentigo malignas, we detected diffuse expression of PTEN in 11 (37%) tumors, widespread loss of PTEN in 11 (37%) tumors and mixed PTEN expression in 8 (27%) lesions. In the primary cutaneous melanomas, PTEN was largely localized to the cytoplasm.
CONCLUSIONS: The presence of PTEN in benign melanocytic tumors and the absence of PTEN in a significant proportion of primary cutaneous melanomas support a role for PTEN loss in the pathogenesis of melanoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14576666     DOI: 10.1016/s0190-9622(03)02473-3

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  31 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

Review 2.  Genetic alterations of PTEN in human melanoma.

Authors:  Almass-Houd Aguissa-Touré; Gang Li
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

3.  Loss of nuclear receptor RXRα in epidermal keratinocytes promotes the formation of Cdk4-activated invasive melanomas.

Authors:  Stephen Hyter; Gaurav Bajaj; Xiaobo Liang; Mariano Barbacid; Gitali Ganguli-Indra; Arup Kumar Indra
Journal:  Pigment Cell Melanoma Res       Date:  2010-07-09       Impact factor: 4.693

4.  The dysplastic nevus: from historical perspective to management in the modern era: part II. Molecular aspects and clinical management.

Authors:  Keith Duffy; Douglas Grossman
Journal:  J Am Acad Dermatol       Date:  2012-07       Impact factor: 11.527

5.  PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.

Authors:  Kim H T Paraiso; Yun Xiang; Vito W Rebecca; Ethan V Abel; Y Ann Chen; A Cecilia Munko; Elizabeth Wood; Inna V Fedorenko; Vernon K Sondak; Alexander R A Anderson; Antoni Ribas; Maurizia Dalla Palma; Katherine L Nathanson; John M Koomen; Jane L Messina; Keiran S M Smalley
Journal:  Cancer Res       Date:  2011-02-11       Impact factor: 12.701

Review 6.  Molecular testing in melanoma.

Authors:  Melissa Ann Wilson; Katherine L Nathanson
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

7.  Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.

Authors:  Hensin Tsao; Vikas Goel; Heng Wu; Guang Yang; Frank G Haluska
Journal:  J Invest Dermatol       Date:  2004-02       Impact factor: 8.551

8.  Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675.

Authors:  Roxana S Dronca; Jacob B Allred; Domingo G Perez; Wendy K Nevala; Elizabeth A T Lieser; Michael Thompson; William J Maples; Edward T Creagan; Barbara A Pockaj; Judith S Kaur; Timothy D Moore; Benjamin T Marchello; Svetomir N Markovic
Journal:  Am J Clin Oncol       Date:  2014-08       Impact factor: 2.339

9.  Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas.

Authors:  Yun Wang; John J Digiovanna; Jere B Stern; Thomas J Hornyak; Mark Raffeld; Sikandar G Khan; Kyu-Seon Oh; M Christine Hollander; Philip A Dennis; Kenneth H Kraemer
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-27       Impact factor: 11.205

10.  Reduced Apaf-1 expression in human cutaneous melanomas.

Authors:  D L Dai; M Martinka; J A Bush; G Li
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.